<DOC>
	<DOCNO>NCT01320917</DOCNO>
	<brief_summary>Obesity disorder associate metabolic dysfunction change cardiovascular risk marker ; use oral contraceptive ( OCs ) may exert negative effect alteration patient PCOS . To assess effect arterial function structure hemostatic parameter use levonorgestrel intrauterine device ( IUS-LNG ) woman obesity A randomized control clinical trial .</brief_summary>
	<brief_title>Levonorgestrel-releasing Intrauterine Device Obese Women : Effects Hemostatic Arterial Function</brief_title>
	<detailed_description>Setting : Academic hospital . 88 woman 18 40 year age obesity ( BMI 20 40 kg/m2 ) randomize use IUS-LNG Copper-IUD 12 month Exclusion criterion : category 3 4 Medical Eligibility Criteria IUD-Cu IUS-LNG - WHO-2010 , pregnancy , lactation , concomitant drug , smoking . Main Outcome Measures : Brachial artery flow-mediated vasodilation , carotid intima-media thickness carotid artery stiffness index evaluate baseline 6 12 month . Serum marker cardiovascular disease hemostatic parameter also analyze .</detailed_description>
	<mesh_term>Hemostatics</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<criteria>Women 18 40 year age obesity grade I II wish use contraceptive clinical condition correspond category 3 4 World Health Organization medical eligibility criterion IUDLNG IUDCU use smoke alcoholism illicit drug use systemic disease ( systemic arterial hypertension , DM , immune system diseases thyroid disease ) except PCOS current previous ( two month study ) use oral , vaginal , monthly injectable transdermal combine hormonal contraceptive current previous use ( six month study ) longlasting hormonal contraceptive method ( injectable , implant intrauterine device ) twelve week less since childbirth currently breastfeed stop breastfeed within two month screen visit chronic and/or acute inflammatory process use drug know interfere inflammatory marker CVD risk ( antiandrogens , hypoglycemic drug , antiinflammatory drug statin )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>obesity</keyword>
	<keyword>contraceptive hormonal</keyword>
	<keyword>levonorgestrel-releasing intrauterine device</keyword>
	<keyword>cardiovascular risk</keyword>
</DOC>